Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling

Heikki Kuusanmäki, Olli Dufva, Elina Parri, Arjan J. van Adrichem, Hanna Rajala, Muntasir M. Majumder, Bhagwan Yadav, Alun Parsons, Wing C. Chan, Krister Wennerberg, Satu Mustjoki, Caroline A. Heckman

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalOncotarget
Volume8
Issue number57
Pages (from-to)97516-97527
Number of pages12
ISSN1949-2553
DOIs
Publication statusPublished - 14 Nov 2017
MoE publication typeA1 Journal article-refereed

Fields of Science

  • STAT3 mutation
  • Hsp90 and JAK inhibitors
  • high-throughput compound screening
  • hematological malignancy
  • GRANULAR LYMPHOCYTIC-LEUKEMIA
  • EPSTEIN-BARR-VIRUS
  • STAT3 MUTATIONS
  • SERINE PHOSPHORYLATION
  • MAXIMAL ACTIVATION
  • MCL-1 EXPRESSION
  • CELL LYMPHOMAS
  • SMALL-MOLECULE
  • INHIBITOR
  • TARGET
  • 3122 Cancers

Cite this